Bayer buys license to Cedilla preclinical cancer program; MEI Pharma says no to unsolicited offer
Bayer has acquired exclusive rights to Cedilla Therapeutics’ preclinical cancer drug candidates for an undisclosed amount.
Bayer announced Thursday morning that it is acquiring the license for Cedilla’s preclinical Cyclin E1/CDK2 complex inhibitors. Cyclin E1 activates CDK2, and the two drive cancer progression and are overexpressed in cancer cells.
Bayer did not disclose what indications it will be pursuing under this partnership. The deal is structured traditionally — Bayer will pay Cedilla an undisclosed amount upfront, and the latter is also eligible for potential development and commercial milestones and royalties. — Lei Lei Wu
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.